Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. (December 2016) - Schaefer, E.; Braiteh, F.; Forster, M.; Talbot, D.; Chandler, J.; Richards, D.; Andre, V.; Estrem, S.; Pitou, C.; Tiu, R.; Brail, L.; Nikolinakos, P.